Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on November 18, 2002

Circulation. 2002
Published online before print November 18, 2002, doi: 10.1161/01.CIR.0000039344.98537.BE
A more recent version of this article appeared on December 10, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/24/3133    most recent
01.CIR.0000039344.98537.BEv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kinoshita, M.
Right arrow Articles by Matsumori, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinoshita, M.
Right arrow Articles by Matsumori, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*HISTAMINE
Related Collections
Right arrow Thrombin

Submitted on December 31, 2001
Revised on September 6, 2002
Accepted on September 10, 2002

Thrombosis Increases Circulatory Hepatocyte Growth Factor by Degranulation of Mast Cells

Makoto Kinoshita MD, Tadashi Miyamoto MD, PhD, Naohiro Ohashi MD, PhD, Shigetake Sasayama MD, PhD, and Akira Matsumori MD, PhD*

From the Department of Cardiovascular Medicine, Kyoto University, Kyoto, Japan.

* To whom correspondence should be addressed. E-mail: amat{at}kuhp.kyoto-u.ac.jp.

Background—Plasma concentrations of hepatocyte growth factor (HGF), a powerful angiogenic growth factor inducible by heparin, increase in thrombus-associated disorders such as myocardial infarction and unstable angina. The mechanism of this thrombus-associated HGF release, however, is unknown.

Methods and Results—Wistar rats received through the tail vein (1) normal saline (NS), (2) 50 µg of the mast cell-degranulating agent CP48/80, or (3) 1000 U/kg heparin. Blood samples were collected at 10 minutes or 30 minutes after the injections, or from untreated rats, for measurements of HGF. The same experiments were performed in mast cell-deficient white spotting (Ws) rats. Ws rats have a small deletion of the c-kit gene and are deficient in mast cells. Intravenous heparin immediately increased plasma HGF in both Wistar (38.02±2.08 ng/mL versus 1.11±0.70 ng/mL in untreated rats, P<0.0001) and Ws rats (36.39±4.15 ng/mL versus 0.66±0.18 ng/mL in NS-treated rats, P<0.0001). Injection of CP48/80 also increased plasma HGF in Wistar rats (9.12±1.11 ng/mL versus 0.65±0.24 ng/mL in NS group, P=0.004) but not in Ws rats (0.67±0.27 ng/mL versus 0.66±0.18 ng/mL in NS group, P=0.997). In a rat carotid artery microthrombus model, intra-arterial thrombus formation increased circulating HGF in Wistar rats (2.12±0.70 ng/mL versus sham 0.61±0.15 ng/mL in sham-operated Wistar rats, P=0.0064) but not in Ws rats (0.76±0.33 ng/mL versus 0.21±0.04 ng/mL in sham-operated Ws rats, P=0.29). In addition, in vitro stimulation of rat peritoneal mast cells with thrombin rapidly induced degranulation in a dose-dependent manner.

Conclusions—These observations indicate that mast cell degranulation stimulated by thrombin is necessary for the rapid induction of plasma HGF in intravascular thrombus-associated disorders.


Key words: growth substances • heparin • thrombus • cells • thrombosis




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
W. W. Raymond, A. C. Cruz, and G. H. Caughey
Mast Cell and Neutrophil Peptidases Attack an Inactivation Segment in Hepatocyte Growth Factor to Generate NK4-like Antagonists
J. Biol. Chem., January 20, 2006; 281(3): 1489 - 1494.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Susen, K. Sautiere, F. Mouquet, F. Cuilleret, A. Chmait, E. P. McFadden, B. Hennache, F. Richard, P. de Groote, J.-M. Lablanche, et al.
Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization
Eur. Heart J., November 2, 2005; 26(22): 2387 - 2395.
[Abstract] [Full Text] [PDF]